포혼 테라퓨틱스(FHTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.13 (-1.67%), 시가총액 $0.22B, 52주 최저~최고 $3.53 ~ $6.68.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhib
포혼 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
포혼 테라퓨틱스의 현재 주가는 $4.13 (-1.67%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
포혼 테라퓨틱스의 시가총액은 약 $0.22B입니다.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulato